{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260812153742/en/Zipalertinib-Plus-Chemotherapy-Meets-Primary-Endpoint-of-Progression-Free-Survival-in-Planned-Interim-Analysis-of-Phase-3-REZILIENT3-Trial-in-First-Line-EGFR-Exon-20-Insertion-Mutation-Non-Small-Cell-Lung-Cancer", "message": "News view counter 880095 successfully enlarged"}